• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pharmasset reports fiscal year financial results

Pharmasset reports fiscal year financial results

November 15, 2011
CenterWatch Staff

Princeton, N.J.-based Pharmasset, a clinical stage pharma company that discovers, develops and commercializes drugs to treat viral infections, reported a net loss of $91.2 million, or $1.25 per share, for the fiscal year ended September 30, 2011, compared to a net loss of $66.1 million, or $1.07 per share for fiscal 2010. Revenues were $0.9 million for fiscal year 2011, compared to $1.0 million for fiscal 2010. Revenues during each fiscal year primarily consist of amortization of up-front and subsequent collaborative and license payments received from Roche previously recorded as deferred revenue. 

Total costs and expenses for the fiscal year were $92.5 million, compared to $64.7 million for fiscal 2010. The increase in operating expenses was primarily the result of increased clinical development costs associated with the initiation and ongoing conduct of the phase II ELECTRON and ATOMIC studies, as well as the advancement of PSI-938 in NUCLEAR and the large phase IIb QUANTUM study.

At fiscal year end Pharmasset held $166.5 million in cash and cash equivalents and used $21.7 million of cash and cash equivalents during the fourth quarter of fiscal 2011.

"In 2011, we have made significant advances with our HCV nucleotide analogs," said Schaefer Price, President and CEO. "Encouraging data in combination with PSI-7977's good safety profile and high barrier to resistance have enabled us to rapidly initiate the first interferon-free phase III program in the industry. We are excited to pursue an interferon-free regimen in phase III, since interferon intolerability keeps most patients from being treated for their HCV. We anticipate filing for marketing approval in the U.S. and Europe in the second half of 2013 and hope to be the first to introduce an interferon-free regimen in the marketplace."

Pharmasset's primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection.

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing